Cost-Effectiveness of Early Asymptomatic Biomarker Detection and Monitoring in Patients with Alzheimer’s Disease: An Explorative Scenario Analysis
Pre-symptomatic intervention without biomarker inclusion has already proven to be cost-effective in Alzheimer patients in the past, but there is a need for further research (Barnett, Lewis, Blackwell & Taylor, 2014; Alzheimer’s Association, 2018). Blood biomarkers seem to be promising to detect onset of AD pre-symptomatic, however, it is often not tested in (human) clinical trials. Therefore, an early economic evaluation is necessary to determine: what is the potential cost-effectiveness of blood test biomarkers? What test characteristics need to be identified in order for blood test biomarkers to be considered cost-effective? What are the added benefits and costs of including blood biomarkers as part of the current diagnostic pathway? The current diagnostic pathway here using MRI and fluorodeoxyglucose PET, due to symptoms. Lastly, what are the long term added benefits and costs of blood test biomarkers for diagnosis and monitoring AD?
Prosjektbeskrivelse med vedlegg
Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.
- Begrunnelse: Data fra literaturen
Prosjektet har ingen godkjenninger